Heron Therapeutics Receives Buy Rating and Positive Outlook

Heron Therapeutics (HRTX) received a Buy rating and a $6 price target from analyst Brandon Folkes at H.C. Wainwright. The company is expected to experience significant growth in its acute care and oncology supportive care sectors, particularly with its product Zynrelef for post-surgical pain. The average analyst target price is $6.33, implying an upside of 201.59% from the current price of $2.10.

Heron Therapeutics (HRTX) has received a Buy rating and a $6 price target from analyst Brandon Folkes at H.C. Wainwright. The biotechnology company, engaged in the commercial phase and offering products in acute care and oncology supportive care sectors, is expected to experience significant growth, particularly with its product Zynrelef for post-surgical pain.

The average analyst target price for Heron Therapeutics is $6.33, implying an upside of 201.59% from the current price of $2.10. The consensus recommendation from brokerage firms is an "Outperform" status, reflecting positive sentiment among analysts.

Heron Therapeutics reported total net revenues of approximately $39 million in Q1 2025, with a record quarterly adjusted EBITDA of $6.2 million and net income of $2.6 million. The oncology franchise, including CINVANTI and SUSTOL, generated combined net revenues of $28.6 million, maintaining market share in a competitive environment. Zynrelef and APONVIE experienced significant growth in Q1 2025, with increases of over 432% and 60% respectively compared to the same period last year.

However, the company faces challenges in sustaining and expanding market share for its products in a highly competitive environment. The onboarding process for new accounts, particularly for Zynrelef, is time-consuming, which may delay the realization of expected sales momentum. Additionally, the company anticipates potential fluctuations in gross profit margins due to varying production scales and costs.

Despite these challenges, Heron Therapeutics is well-positioned for growth, with a strong pipeline of products and a favorable outlook from analysts. The company's ability to navigate these challenges and capitalize on growth opportunities will be crucial for its future success.

References:
[1] https://www.gurufocus.com/news/2914756/heron-therapeutics-hrtx-gains-buy-rating-and-positive-outlook-hrtx-stock-news
[2] https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrtx/heron-therapeutics